$6.9M NIAID Award to Fund Design, Testing of Hepatitis C Vaccine

Team Takes on Virus Behind Liver Disease in Tens of Millions Globally

By Nicole Tenly Aug 24, 2022

The National Institute of Allergy and Infectious Disease (NIAID) awarded $6.9 million to researchers at the Institute for Bioscience and Biotechnology Research (IBBR) to design a vaccine to combat the virus that causes Hepatitis C (HCV), which affects an estimated 71 million people worldwide and puts them at risk for severe liver disease, including cancer.
This five-year award will support a multidisciplinary research team based at IBBR, a joint research enterprise of the University of Maryland, College Park (UMCP), the University of Maryland, Baltimore (UMB) and the National Institute of Standards and Technology (NIST). The researchers aim to develop a vaccine to induce broadly neutralizing antibodies and long-term memory T cell responses to help prevent HCV infection. This recent award follows a $6 million grant awarded to the IBBR research team in 2017 based on its significant progress in the field.

​TO CONTINUE: https://today.umd.edu/6-9m-niaid-award-to-fund-design-testing-of-hepatitis-c-vaccine